Small Interfering Ribonucleic Acid (RNA) Market Report 2026

The small interfering ribonucleic acid (rna) market size has grown exponentially in recent years. It will grow from $18.86 billion in 2025 to $22.69 billion in 2026 at a compound annual growth rate (CAGR) of 20.3%. The growth in the historic period can be attributed to advancements in molecular biology research, rising prevalence of genetic and chronic diseases, early success of rna-based therapeutics, increased research funding in genomics, establishment of rna interference mechanisms.

The small interfering ribonucleic acid (rna) market size is expected to see exponential growth in the next few years. It will grow to $47.07 billion in 2030 at a compound annual growth rate (CAGR) of 20%. The growth in the forecast period can be attributed to increasing regulatory approvals for rna therapies, growing demand for personalized medicine, expansion of nanoparticle delivery innovations, rising investments by pharmaceutical companies, broader application of sirna in infectious and rare diseases. Major trends in the forecast period include increasing clinical adoption of rna interference therapies, growing focus on targeted gene silencing approaches, expansion of advanced sirna delivery platforms, rising investment in precision therapeutics development, enhanced emphasis on scalable rna manufacturing.

The increasing demand for personalized medicine is anticipated to drive the growth of the small interfering ribonucleic acid (RNA) market in the coming years. Personalized medicine is a medical strategy that customizes treatments for individual patients based on their genetic, environmental, and lifestyle factors to enhance outcomes and improve care. The demand for personalized medicine is rising due to advances in genomic technologies, which allow for the accurate identification of genetic variations and the development of tailored treatments for patients. Small interfering ribonucleic acid (siRNA) supports personalized medicine by enabling precise gene silencing, making it effective for treating specific genetic disorders and diseases. It minimizes off-target effects by selectively inhibiting disease-causing mRNA, thereby improving therapeutic efficacy and patient outcomes. For example, in February 2024, according to the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, up from 12 approvals in 2022. Consequently, the growing demand for personalized medicine is fueling the expansion of the small interfering ribonucleic acid (RNA) market.

Major companies operating in the small interfering ribonucleic acid (siRNA) therapeutics market are concentrating on obtaining regulatory approvals for innovative mechanisms to treat rare genetic disorders, aiming to provide long-lasting effects and minimize dosing frequency for patients. Regulatory approvals are official authorizations from authorities permitting a drug or therapy to be safely tested, marketed, or administered to patients. For example, in March 2025, Alnylam Pharmaceuticals Inc., a US-based biopharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for Qfitlia (fitusiran), the first small interfering ribonucleic acid (siRNA)-based therapy for adults and adolescents aged 12 years and older with hemophilia A or B, with or without inhibitors. The therapy is designed to reduce antithrombin levels, thereby increasing thrombin generation to support clot formation and decrease bleeding episodes. Qfitlia provides a subcutaneous, once-every-two-month dosing schedule, offering a novel, non-factor therapeutic option for hemophilia management.

In May 2025, AbbVie Inc., a US-based biopharmaceutical company, formed a partnership with ADARx Pharmaceuticals Inc. Through this collaboration, AbbVie Inc. aims to combine ADARx Pharmaceuticals Inc.’s proprietary RNA technology with its scientific expertise to develop next-generation small interfering RNA (siRNA) therapies, advancing progress in neuroscience, immunology, and oncology. ADARx Pharmaceuticals Inc. is a biotechnology company focused on developing small interfering ribonucleic acid (siRNA)-based therapies that target specific mRNA to treat diseases.

Major companies operating in the small interfering ribonucleic acid (rna) market are Novartis AG, Thermo Fisher Scientific Inc., GlaxoSmithKline plc, Sanofi S.A., Sarepta Therapeutics Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Wave Life Sciences Ltd., Silence Therapeutics plc, Arrowhead Pharmaceuticals Inc., Quark Pharmaceuticals Inc., Arbutus Biopharma Corporation, Evox Therapeutics Ltd., Phio Pharmaceuticals Inc., Genecon Biotechnologies Co. Ltd., Olix Pharmaceuticals Inc., Benitec Biopharma Ltd., Bio-Path Holdings Inc., Calando Pharmaceuticals Inc., Sirnaomics Ltd.

North America was the largest region in the small interfering ribonucleic acid (RNA) market in 2025. The regions covered in the small interfering ribonucleic acid (rna) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the small interfering ribonucleic acid (rna) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the small interfering ribonucleic acid market by increasing costs of imported nucleotides, lipid nanoparticles, specialized reagents, laboratory instruments, and advanced manufacturing equipment required for siRNA synthesis and delivery. Research institutions and pharmaceutical companies in North America and Europe are most affected due to dependence on imported high-purity raw materials, while Asia-Pacific faces cost pressures on export-oriented production. These tariffs are raising development and production costs and extending clinical timelines. However, they are also encouraging local sourcing of reagents, domestic manufacturing of RNA components, and regional expansion of biopharmaceutical production capabilities.

The small interfering ribonucleic acid (rna) market research report is one of a series of new reports that provides small interfering ribonucleic acid (rna) market statistics, including small interfering ribonucleic acid (rna) industry global market size, regional shares, competitors with a small interfering ribonucleic acid (rna) market share, detailed small interfering ribonucleic acid (rna) market segments, market trends and opportunities, and any further data you may need to thrive in the small interfering ribonucleic acid (rna) industry. This small interfering ribonucleic acid (rna) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Small interfering ribonucleic acid (RNA) is a short, double-stranded RNA molecule that is crucial for gene silencing through a mechanism known as RNA interference (RNAi). It attaches to complementary messenger RNA (mRNA) sequences, resulting in their degradation and blocking protein production. The main function of siRNA is to control or reduce the expression of specific genes and is often utilized in research and therapeutic settings to target genes that cause diseases.

The main types of small interfering ribonucleic acid (RNA) include liposome-based systemic therapy and nanoparticle-based systemic therapy. Liposome-based systemic therapy is a drug delivery method that utilizes liposomes to carry therapeutic agents throughout the body via the bloodstream. These therapies are applied for various conditions, including cardiovascular diseases, respiratory diseases, oncology, neurodegenerative diseases, and infectious diseases, and serve end users such as hospitals, research institutions, pharmaceutical and biotechnology companies, and academic institutions.

The small interfering ribonucleic acid (RNA) market consists of revenues earned by entities by providing services such as gene silencing assays, delivery system development, molecular diagnostics, preclinical testing, and laboratory research support. The market value includes the value of related goods sold by the service provider or included within the service offering. The small interfering ribonucleic acid (RNA) market also includes sales of synthesis kits, lipid nanoparticles, delivery vectors, RNAi assay kits, transfection reagents, and RNA extraction kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.